COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC).


Journal

ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685

Informations de publication

Date de publication:
06 2021
Historique:
received: 25 03 2021
revised: 05 05 2021
accepted: 05 05 2021
pubmed: 31 5 2021
medline: 20 7 2021
entrez: 30 5 2021
Statut: ppublish

Résumé

Italy was among the first countries hit by the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The application of strict lockdown measures disproportionately affected both cancer patient care as well as basic and translational cancer research. The Italian Cancer Society (SIC) conducted a survey on the effect of lockdown on laboratories involved in cancer research in Italy. The survey was completed by 570 researchers at different stages of their career, working in cancer centers, research institutes and universities from 19 Italian regions. During the lockdown period, the impact of the COVID-19 pandemic emergency on face-to-face research activities was high, with a complete (47.7%) or partial (36.1%) shutdown of the laboratories. In the post-lockdown period, research activities were resumed in most of the respondents' institutions (80.4%), though with some restrictions (77.2%). COVID-19 testing was offered to research personnel only in ~50% of research institutions. Overall, the response to the pandemic was fragmented as in many cases institutions adopted different strategies often aimed at limiting possible infections without a clearly defined contingency plan. Nevertheless, research was able to provide the first answers and possible ways out of the pandemic, also with the contribution of many cancer researchers that sacrificed their research programs to help overcome the pandemic by offering their knowledge and technologies. Given the current persistence of an emergency situation in many European countries, a more adequate organization of research centers will be urgent and necessary to ensure the continuity of laboratory activities in a safe environment.

Sections du résumé

BACKGROUND
Italy was among the first countries hit by the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The application of strict lockdown measures disproportionately affected both cancer patient care as well as basic and translational cancer research.
MATERIALS AND METHODS
The Italian Cancer Society (SIC) conducted a survey on the effect of lockdown on laboratories involved in cancer research in Italy. The survey was completed by 570 researchers at different stages of their career, working in cancer centers, research institutes and universities from 19 Italian regions.
RESULTS
During the lockdown period, the impact of the COVID-19 pandemic emergency on face-to-face research activities was high, with a complete (47.7%) or partial (36.1%) shutdown of the laboratories. In the post-lockdown period, research activities were resumed in most of the respondents' institutions (80.4%), though with some restrictions (77.2%). COVID-19 testing was offered to research personnel only in ~50% of research institutions. Overall, the response to the pandemic was fragmented as in many cases institutions adopted different strategies often aimed at limiting possible infections without a clearly defined contingency plan. Nevertheless, research was able to provide the first answers and possible ways out of the pandemic, also with the contribution of many cancer researchers that sacrificed their research programs to help overcome the pandemic by offering their knowledge and technologies.
CONCLUSIONS
Given the current persistence of an emergency situation in many European countries, a more adequate organization of research centers will be urgent and necessary to ensure the continuity of laboratory activities in a safe environment.

Identifiants

pubmed: 34052554
pii: S2059-7029(21)00125-3
doi: 10.1016/j.esmoop.2021.100165
pmc: PMC8176317
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100165

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure The authors have declared no conflicts of interest.

Auteurs

F Bianchi (F)

Fondazione IRCCS Casa Sollievo della Sofferenza, Cancer Biomarkers Unit, San Giovanni Rotondo, Italy.

E Dama (E)

Fondazione IRCCS Casa Sollievo della Sofferenza, Cancer Biomarkers Unit, San Giovanni Rotondo, Italy.

F Di Nicolantonio (F)

Department of Oncology, University of Torino, Candiolo, Turin, Italy; Candiolo Cancer Institute, Candiolo, Turin, Italy.

G Baldassarre (G)

Molecular Oncology Unit Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.

I Guerriero (I)

Biogem, Institute for Genetic Research 'G. Salvatore', Ariano Irpino, Italy.

E Torchiaro (E)

Candiolo Cancer Institute, Candiolo, Turin, Italy.

A Bruno (A)

Laboratory of Immunology, Unit of Molecular Pathology, Immunology and Biochemistry, IRCCS MultiMedica, Milan, Italy.

G Blandino (G)

Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

P Allavena (P)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.

P Chiarugi (P)

Department of Experimental and Clinical Biomedical Sciences, School of Medicine, University of Florence, Florence, Italy.

G Sozzi (G)

Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

M D'Incalci (M)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

N Normanno (N)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy. Electronic address: n.normanno@istitutotumori.na.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH